Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, Yale University School of Medicine, New Haven, Connecticut, USA.
Otolaryngol Head Neck Surg. 2024 Oct;171(4):1017-1026. doi: 10.1002/ohn.817. Epub 2024 May 20.
In 2022, the Food and Drug Administration established a new regulatory category for over-the-counter (OTC) hearing aids for mild to moderate hearing loss. Herein, we aim to better compare the safety and efficacy of these devices to that of prescription hearing aids.
Comparative-effectiveness model.
Academic Audiology Center.
The safety and efficacy of prescription and OTC hearing aids was compared using the AudioScan Verifit 2 Testbox software. Three types of hearing loss (downsloping, sharp downsloping, and reverse sloping) were analyzed. Efficacy was tested at 3 volume inputs and was measured by calculating the average difference in test points (produced by the devices) and target points (estimated by the software). Safety was assessed by calculating the average difference in test points and the maximally safe hearing level (produced by the software).
Prescription hearing aids were found to have a better safety profile by being further from the safety threshold compared to OTC devices at the 8000 Hz frequency for the 2 types of downsloping hearing loss patterns studied (48 vs 30.5 dB, P = .04; 51 vs 32.5 dB, P = .03). Prescription hearing aids also carried a statistically significant advantage at 3 test points. OTC hearing aids generally had a greater difference between test and target points.
OTC and prescription hearing aids are comparably safe, though OTC hearing aids are slightly less efficacious. Further evaluation of the OTC hearing aid efficacy is warranted to ensure it provides the gain of benefit needed for different types of hearing loss.
2022 年,美国食品和药物管理局为轻度至中度听力损失设立了一个新的非处方(OTC)助听器监管类别。在此,我们旨在更好地比较这些设备的安全性和疗效与处方助听器。
比较有效性模型。
学术听力学中心。
使用 AudioScan Verifit 2 Testbox 软件比较处方和 OTC 助听器的安全性和疗效。分析了三种听力损失类型(下降型、急剧下降型和反向下降型)。在 3 个音量输入下测试疗效,并通过计算测试点(设备产生)和目标点(软件估计)之间的平均差异进行测量。安全性通过计算测试点和最大安全听力水平(软件产生)之间的平均差异进行评估。
与 OTC 设备相比,处方助听器在 8000Hz 频率下对于研究的 2 种下降型听力损失模式具有更好的安全性,距离安全阈值更远(48 与 30.5dB,P=0.04;51 与 32.5dB,P=0.03)。处方助听器在 3 个测试点也具有统计学优势。OTC 助听器的测试点和目标点之间的差异通常更大。
OTC 和处方助听器的安全性相当,尽管 OTC 助听器的疗效略低。需要进一步评估 OTC 助听器的疗效,以确保其提供不同类型听力损失所需的增益益处。